

**PATENT ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
------------------	----------------

NATURE OF CONVEYANCE:	ASSIGNMENT
-----------------------	------------

CONVEYING PARTY DATA	
Name	Execution Date
Resistentia Pharmaceuticals AB	02/02/2009

RECEIVING PARTY DATA	
Name:	Resistentia Holding AB
Street Address:	Kungsangsvagen 25, Box 853
City:	Uppsala
State/Country:	SWEDEN
Postal Code:	SE-751 08

PROPERTY NUMBERS Total: 10	
Property Type	Number
Application Number:	11551510
Application Number:	12099332
Patent Number:	7361742
Application Number:	11746382
Patent Number:	7232898
Application Number:	10453915
Application Number:	10176664
Application Number:	09723945
Patent Number:	6913749
Patent Number:	5653980

CORRESPONDENCE DATA	
Fax Number:	(877)769-7945
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	(612) 335-5070
Email:	jwright@fr.com

CH \$400.00 11551510

Correspondent Name: Elizabeth N. Kaytor  
Address Line 1: FISH & RICHARDSON P.C.  
Address Line 2: P.O.BOX 1022  
Address Line 4: MINNEAPOLIS, MINNESOTA 55440-1022

ATTORNEY DOCKET NUMBER:

10223-0001001

NAME OF SUBMITTER:

Elizabeth N. Kaytor

Total Attachments: 3  
source=10223assign#page1.tif  
source=10223assign#page2.tif  
source=10223assign#page3.tif

## ASSIGNMENT OF PATENT RIGHTS

Assignor: Resistentia Pharmaceuticals AB  
Kungsängsvägen 25, Box 853  
SE-751 08  
Uppsala, Sweden

Assignee: Resistentia Holding AB  
Kungsängsvägen 25, Box 853  
SE-751 08  
Uppsala, Sweden

Issued Patent No. 5,653,980, filed September 25, 1992

Issued Patent No. 6,913,749, filed September 22, 1999

---

Serial No. 09/723,945, filed November 28, 2000

Serial No. 10/176,664, filed June 19, 2002

Serial No. 10/453,915, filed June 2, 2003

Issued Patent No. 7,232,898, filed May 15, 2003

Serial No. 11/746,382, filed May 9, 2007

Issued Patent No. 7,361,742, filed December 1, 2003


Serial No. 12/099,332, filed April 8, 2008

Serial No. 11/551,510, filed October 20, 2006

1. Pursuant to the terms and conditions of the agreement entitled "Asset Transfer Agreement" (the "Agreement"), which was signed October 1, 2008, this Assignment is effective on that date.
2. Assignor represents that it is the exclusive owner of the inventions described in the Patents and Patent Applications listed above, and all related foreign and domestic patents, patent applications, provisionals, divisionals, continuations, continuations-in-part, reissues, re-examinations, certificates of invention, and the like that may issue from


or which derive priority from the listed Patents and Patent Applications (all of which are collectively referred to as the "Patent Rights"). Assignor represents that Assignor has the full right to convey the interest assigned by this Assignment, and that Assignor has not executed and will not execute any agreement in conflict with this Assignment.

2. Assignor assigns to Assignee the entire worldwide right, title, and interest in and to the Patent Rights, and acknowledges receipt of fair and adequate consideration for such Assignment.
3. Assignor assigns to Assignee all the Assignor's right, title, and interest in and to any claims (known or unknown, suspected or unsuspected) of any nature that Assignor has or may have against any party for infringement of the Patent Rights, and acknowledges receipt of fair and adequate consideration for such Assignment.
4. Assignor authorizes and requests the Commissioner of Patents to issue any and all Letters Patent of the United States resulting from any patent application within the Patent Rights to Assignee, as the Assignee of the entire interest therein.
5. This agreement is binding upon and inures to the benefit of the successors and assigns of the parties.
6. Pursuant to the Agreement, this Assignment is executed by Resistentia Pharmaceuticals AB with the effective date of this Agreement and Assignment, which, as indicated above, is October 1, 2008.

  
\_\_\_\_\_


Jonas Brambeck  
Resistentia Pharmaceuticals AB

2009-02-02  
Date

  
\_\_\_\_\_

Johan Christenson  
Resistentia Pharmaceuticals AB

2009-02-02  
Date

  
\_\_\_\_\_

Witness Signature

Claes Lundberg  
\_\_\_\_\_

Witness Printed Name